Rekombinanter VEGFA (Brolucizumab Biosimilar) Antikörper

Produktnummer ABIN7795130

Dieser Maus Monoklonal Antikörper detektiert spezifisch VEGFA (Brolucizumab Biosimilar) in FACS und in vivo. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Rekombinanter VEGFA (Brolucizumab Biosimilar) Antikörper (ABIN7795130)

Target: VEGFA (Brolucizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-VEGFA (Brolucizumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody

Produktmerkmale: Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab. Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human VEGF-A

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu VEGFA (Brolucizumab Biosimilar)

Target: VEGFA (Brolucizumab Biosimilar)

Andere Bezeichnung: Brolucizumab Biosimilar

Substanzklasse: Biosimilar